  Recent studies have identified highly tumorigenic cells with stem cell-like
characteristics in human cancers, termed cancer stem cells (CSCs). CSCs are
resistant to conventional radiotherapy and chemotherapy owing to their high DNA
repair ability and oncogene overexpression. However, the mechanisms regulating
CSC radio-resistance, particularly proton beam resistance, remain unclear. We
isolated CSCs from the breast cancer cell lines MCF-7 and MDA-MB-231, which
expressed the characteristic breast CSC membrane protein markers
CD44+/CD24-/low, and irradiated the CSCs with pulsed proton beams. We confirmed
that CSCs are resistant to pulsed proton beams and showed that treatment with
p38 and ERK inhibitors reduced CSC radioresistance. Based on these results,
BCSC radio-resistance can be reduced during proton beam therapy by co-treatment
with ERK1/2 or p38 inhibitors, representing a novel approach for breast cancer
therapy.
